New drug combo aims to boost Radiation's punch against head and neck cancer
NCT ID NCT01783587
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested the safety of adding the drug afatinib to standard radiation therapy for people with head and neck cancer at risk of recurrence. Afatinib blocks proteins that help cancer grow and may make cancer cells more sensitive to radiation. The study included 29 participants and aimed to find the safest dose of afatinib when given with radiation, with or without chemotherapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02115, United States
-
Mount Sinai Medical Center/Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Pre-Surgery immunotherapy prime the immune system to fight head and neck cancer?
- Can a new drug boost the power of chemoradiation against head and neck cancer?
- Experimental antibody combo aims to boost immune attack on head and neck tumors
- Scientists hunt for blood markers to unmask hidden aggressive tumors
- Liver damage study in head and neck cancer abandoned after just 2 patients
- New antibody drug takes aim at Hard-to-Treat cancers